With Shire Behind Him, Jonas Starts New Chapter At SAGE
This article was originally published in The Pink Sheet Daily
The upbeat ex-Shire exec has moved on from his tumultuous break-up with the specialty pharma and is on day three in his new role as CEO of CNS start-up SAGE Therapeutics. He will focus on bringing CNS products forward for orphan indications.
You may also be interested in...
Recently public Akebia is just one of the many biotechs making a case for spin-outs driven by economic needs. Also, Sangamo, Ataxion, Galmed and SAGE tap the financing pool.
The Irish specialty pharma has divested an underperforming unit, but not without a significant write-off. Yet, investors and analysts applaud the decision.
ARCH Venture Partners joined original investor Third Rock Ventures in backing the Cambridge, Mass., start-up with $20 million in Series B money. SAGE is concentrating its efforts on several compounds, including one to treat a type of epileptic seizure, which could represent the beginning of a larger epilepsy franchise.